Explore
Validate
Learn500-P108-1MG
antibody from Invitrogen Antibodies
Targeting: CCL18
AMAC-1, CKb7, DC-CK1, DCCK1, MIP-4, PARC, SCYA18
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Western blot [2]
- ELISA [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 500-P108-1MG - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- MIP-4 Polyclonal Antibody, PeproTech®
- Antibody type
- Polyclonal
- Antigen
- Recombinant full-length protein
- Description
- AA Sequence of recombinant protein: QVGTNKELCC LVYTSWQIPQ KFIVDYSETS PQCPKPGVIL LTKRGRQICA DPNKKWVQKY ISDLKLNA.
- Concentration
- 0.1-1.0 mg/mL
Submitted references Differential dermal expression of CCL17 and CCL18 in tuberculoid and lepromatous leprosy.
PARC/CCL18 is a plasma CC chemokine with increased levels in childhood acute lymphoblastic leukemia.
Unique regulation of CCL18 production by maturing dendritic cells.
Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma.
Berrington WR, Kunwar CB, Neupane K, van den Eeden SJ, Vary JC Jr, Peterson GJ, Wells RD, Geluk A, Hagge DA, Hawn TR
PLoS neglected tropical diseases 2014;8(11):e3263
PLoS neglected tropical diseases 2014;8(11):e3263
PARC/CCL18 is a plasma CC chemokine with increased levels in childhood acute lymphoblastic leukemia.
Struyf S, Schutyser E, Gouwy M, Gijsbers K, Proost P, Benoit Y, Opdenakker G, Van Damme J, Laureys G
The American journal of pathology 2003 Nov;163(5):2065-75
The American journal of pathology 2003 Nov;163(5):2065-75
Unique regulation of CCL18 production by maturing dendritic cells.
Vulcano M, Struyf S, Scapini P, Cassatella M, Bernasconi S, Bonecchi R, Calleri A, Penna G, Adorini L, Luini W, Mantovani A, Van Damme J, Sozzani S
Journal of immunology (Baltimore, Md. : 1950) 2003 Apr 1;170(7):3843-9
Journal of immunology (Baltimore, Md. : 1950) 2003 Apr 1;170(7):3843-9
Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma.
Schutyser E, Struyf S, Proost P, Opdenakker G, Laureys G, Verhasselt B, Peperstraete L, Van de Putte I, Saccani A, Allavena P, Mantovani A, Van Damme J
The Journal of biological chemistry 2002 Jul 5;277(27):24584-93
The Journal of biological chemistry 2002 Jul 5;277(27):24584-93
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot: To detect Human MIP-4 (CCL18) by Western Blot analysis MIP-4 Polyclonal Antibody (Product # 500-P108-1MG) can be used at a concentration of 0.1-0.2 µg/mL. Used in conjunction with compatible secondary reagents the detection limit for Recombinant Human MIP-4 (CCL18) is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot: To detect Human MIP-4 (CCL18) by Western Blot analysis MIP-4 Polyclonal Antibody (Product # 500-P108-1MG) can be used at a concentration of 0.1-0.2 µg/mL. Used in conjunction with compatible secondary reagents the detection limit for Recombinant Human MIP-4 (CCL18) is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Sandwich ELISA: To detect Human MIP-4 (CCL18) by sandwich ELISA (using 100 µL/well antibody solution) a concentration of 0.5-2.0 µg/mL of MIP-4 Polyclonal Antibody (Product # 500-P108-1MG) is required. This antigen affinity purified antibody, in conjunction with PeproTech MIP-4 Polyclonal Antibody, Biotin (Product # 500-P108BT-1MG) as a detection antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant Human MIP-4 (CCL18).
